BioSpace News Archive

I-Mab Biopharma (“I-Mab”), a global biopharmaceutical company based in China and the United States and focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases today announced the dosing of the first patient in mainland China in its registrational study evaluating its human CD38 antibody (TJ202/MOR202) in patients with relapsed or refractory multiple myeloma (MM).

Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report its first quarter financial results for fiscal year 2020, the period ended November 30, 2019, after the close of the financial markets on Thursday, January 9, 2020.

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of HemaCare Corporation (OTCMKTS: HEMA) for approximately $380 million in cash, or $25.40 per HemaCare share. HemaCare will become part of Charles River’s Research Models and Services segment.

A healthy holiday season challenge at Unilever’s Jonesboro location spread cheer through the region with employees experiencing comprehensive preventive health exams and their collective effort earning a donation to the Food Bank of Northeast Arkansas.

Leap Therapeutics, Inc. (Nasdaq: LPTX), and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), today announced an exclusive option and license agreement for the clinical development and commercialization of DKN-01, Leap’s anti-Dickkopf-1

McKesson Corporation (NYSE:MCK) announced today that its third quarter fiscal 2020 financial results will be released before market open on Tuesday, February 4, 2020.

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, announces that it was notified on 31 December 2019 that Mr Richard Hullihen, the Company’s CEO, has purchased a total of 347,100 ordinary shares of £0.00037

Thermo Fisher Scientific and Agilent Technologies today announced they are continuing their agreement to the industry-wide Instrument Control Exchange Program (ICEP) – fostering compatibility among key vendors’ instrumentation and chromatography data systems (CDS)

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that JJ Pellegrino, Chief Financial Officer, will present at the 22nd Annual Needham Growth Conference on Wednesday, January 15, 2020